Note: This article is for educational publishing purposes only and should not replace diagnosis, treatment, or medication advice from a licensed dermatologist or healthcare professional.
Why Hidradenitis Suppurativa Research Matters Right Now
Hidradenitis suppurativa, often shortened to HS, is one of those skin conditions that sounds rare until you meet someone living with it. Then you realize it is not just “a few bumps.” It is a chronic inflammatory disease that can cause painful nodules, abscesses, draining tunnels, scarring, sleep disruption, anxiety, missed school or work, and the daily wardrobe strategy of a tactical field commander.
For years, many patients were told they had boils, ingrown hairs, acne, poor hygiene, or “just sensitive skin.” Spoiler alert: HS is not caused by being dirty. It is an inflammatory disease involving hair follicles, immune signaling, genetics, hormones, the skin microbiome, friction, and environmental triggers. The disease usually appears in areas where skin rubs together, such as the armpits, groin, inner thighs, buttocks, and under the breasts.
The exciting part is that hidradenitis suppurativa research has entered a much more serious phase. Instead of treating HS only with antibiotics, drainage, and crossed fingers, dermatology is moving toward targeted therapies that aim at specific inflammatory pathways. New biologics, oral immune-modulating drugs, laser approaches, surgical strategies, microbiome studies, and clinical trials are changing the conversation from “How do we calm this flare?” to “How do we control the disease long-term?”
Understanding HS Before Talking About New Treatments
To understand why new hidradenitis suppurativa treatments matter, it helps to understand what researchers are trying to interrupt. In HS, hair follicles can become blocked and inflamed. The immune system then behaves like a smoke alarm that not only detects smoke but also orders a marching band, fireworks, and a fog machine. This exaggerated inflammatory response can lead to painful lumps, abscesses, pus drainage, and tunnel-like tracts under the skin.
Doctors often describe HS severity using the Hurley staging system. Hurley stage I usually means isolated abscesses without tunnels or extensive scarring. Hurley stage II involves recurring abscesses with scarring and sinus tracts. Hurley stage III is more widespread, with interconnected tunnels and chronic inflammation. The stage does not tell the whole story, because pain, drainage, location, and mental health burden also matter, but it gives clinicians a practical starting point.
Traditional HS treatment may include antibacterial washes, topical antibiotics, oral antibiotics, hormonal therapy, pain control, lifestyle support, laser hair reduction, deroofing, and surgical excision. These still matter. The research boom does not mean every patient needs a biologic on day one. It means clinicians now have more tools, and ideally, fewer people are stuck in the old cycle of “antibiotics, temporary improvement, flare, repeat.”
The Current Treatment Landscape: From Antibiotics to Biologics
For mild disease, dermatologists may start with topical clindamycin, antiseptic washes, weight-management support when appropriate, smoking cessation support, loose clothing, friction reduction, and flare tracking. For more active or widespread HS, oral antibiotics such as doxycycline or a combination of clindamycin and rifampin may be used. These medicines can reduce inflammation and bacterial load, but they do not always provide lasting control.
Hormonal approaches can help some patients, especially when flares appear linked to menstrual cycles. Options may include combined oral contraceptives, spironolactone, or metformin in selected cases. These are not magic wands, but for the right patient, they can be surprisingly useful. HS is a condition where “one-size-fits-all” treatment deserves to be thrown into the nearest laundry basket.
For moderate-to-severe hidradenitis suppurativa, biologic therapy has become one of the most important research-driven advances. Biologics are medicines designed to target specific immune pathways. Instead of broadly suppressing the immune system like a clumsy bouncer at a crowded club, they focus on particular inflammatory signals involved in disease activity.
FDA-Approved Biologics: The Big Shift in HS Care
Adalimumab: The First Major Biologic Milestone
Adalimumab, sold under the brand name Humira and also available as biosimilars, was the first FDA-approved biologic for moderate-to-severe hidradenitis suppurativa. It targets tumor necrosis factor-alpha, commonly called TNF-alpha, a major inflammatory protein. For many patients, adalimumab changed HS treatment from “manage the mess” to “reduce the inflammatory engine.”
However, not everyone responds. Some patients improve dramatically, some improve partially, and others do not get enough benefit. Some lose response over time. This is one reason research has expanded into other pathways, especially interleukin-17, interleukin-1, JAK signaling, and other immune targets.
Secukinumab: IL-17A Enters the HS Conversation
Secukinumab, known by the brand name Cosentyx, targets interleukin-17A. IL-17 is an inflammatory pathway already familiar in psoriasis and psoriatic arthritis, and researchers have found that it also plays an important role in HS inflammation. The approval of secukinumab gave dermatologists another targeted option for adults with moderate-to-severe disease, especially patients who did not respond well enough to TNF-alpha inhibition.
This matters because HS is not a single-lane road. Two patients may have similar-looking lesions but very different immune patterns, pain levels, tunnel formation, and response to treatment. Adding an IL-17A inhibitor expands the menu beyond TNF-alpha, and in HS, more menu options are not a luxury; they are survival equipment.
Bimekizumab: Dual IL-17A and IL-17F Blocking
Bimekizumab, sold as Bimzelx, is another major development. It targets both IL-17A and IL-17F, two related inflammatory proteins. Research leading to approval showed that blocking both signals may help reduce inflammatory lesions in moderate-to-severe HS. For patients and clinicians, bimekizumab represents a more refined IL-17 strategy and another sign that HS treatment is becoming more biologically precise.
The key point is not that one biologic is automatically “best.” HS therapy depends on disease severity, prior treatment response, other medical conditions, infection risk, pregnancy plans, insurance coverage, patient preference, and tolerance for injections. The real progress is that dermatologists now have multiple approved biologic choices rather than one lonely option standing in the corner wearing a “please pick me” badge.
New Treatments in the Pipeline
Povorcitinib: The Oral JAK Inhibitor to Watch
One of the most closely watched HS clinical trial drugs is povorcitinib, an oral JAK1 inhibitor. JAK inhibitors affect intracellular signaling pathways that help transmit inflammatory messages. In plain English, they interfere with the cellular group chat that keeps telling inflammation to show up with a megaphone.
Phase 3 studies of povorcitinib have focused on adults with moderate-to-severe hidradenitis suppurativa. Trial programs have measured outcomes such as HiSCR50, meaning at least a 50% reduction in abscess and inflammatory nodule count without worsening in abscesses or draining tunnels. The appeal is obvious: an effective oral option could be valuable for patients who dislike injections, have not responded to biologics, or need a different mechanism of action.
Still, oral immune-modulating drugs require careful safety monitoring. JAK inhibitors may carry risks that need to be weighed individually, including infection risks and lab monitoring concerns. The excitement is real, but so is the fine print. Medicine, unfortunately, does not come with a “skip terms and conditions” button.
Sonelokimab: A Nanobody Targeting IL-17A and IL-17F
Sonelokimab is another promising investigational therapy. It is designed as a nanobody that targets IL-17A and IL-17F, and clinical research has evaluated it in moderate-to-severe HS. The idea is similar in spirit to dual IL-17 targeting, but the molecular design is different. Researchers are studying whether this structure may improve tissue penetration or clinical response.
Clinical trial results have drawn attention because researchers are increasingly looking beyond basic lesion reduction. They are also watching draining tunnels, pain, quality of life, and high-level response thresholds such as HiSCR75 or HiSCR100. That is important because a 50% improvement may be meaningful, but for someone planning their day around bandages, spare clothes, and whether sitting hurts, deeper response is the dream.
Izokibep: Another IL-17A Approach
Izokibep is an investigational IL-17A inhibitor being studied in hidradenitis suppurativa. It is designed as a small protein therapeutic with high binding affinity to IL-17A. Research has included patients with active HS, including people who have not used TNF inhibitors and those who had inadequate response or intolerance to them.
The broader lesson is that IL-17 biology has become one of the hottest neighborhoods in HS research. Scientists are not simply asking, “Does IL-17 matter?” They are asking which IL-17 signal, which drug structure, which dosing strategy, and which patient profile might produce the best outcomes.
Lutikizumab: Targeting Interleukin-1 Alpha and Beta
Lutikizumab is an investigational therapy that blocks both interleukin-1 alpha and interleukin-1 beta. IL-1 is another inflammatory pathway believed to contribute to HS. This area is especially interesting because HS lesions often involve intense local inflammation, tissue damage, and immune activation.
Research into IL-1 blockers reflects a wider shift: HS is no longer being treated as “just skin.” It is an immune-mediated inflammatory disease with skin symptoms, systemic associations, pain signals, and quality-of-life effects. That shift sounds academic, but for patients, it can mean being taken seriously instead of being handed another short antibiotic course and a sympathetic shrug.
Spesolimab and IL-36 Research
Spesolimab targets the interleukin-36 receptor and is being studied in inflammatory skin disease. IL-36 has drawn attention because it may contribute to inflammatory loops in certain skin conditions. Clinical trials in HS are part of the effort to map which immune pathways actually drive disease activity and which are merely standing nearby looking suspicious.
Not every investigational drug will succeed. Some will look good in early studies and then disappoint in larger trials. That is not failure in the big-picture sense. It is how science separates promising ideas from treatments that truly help real patients outside the carefully controlled world of clinical research.
Clinical Trials: What Researchers Are Measuring
HS clinical trials commonly measure the Hidradenitis Suppurativa Clinical Response, or HiSCR. The traditional HiSCR50 endpoint means the patient has at least a 50% reduction in abscesses and inflammatory nodules without an increase in abscesses or draining tunnels. Newer studies may also examine HiSCR75, HiSCR90, or HiSCR100, which represent deeper levels of response.
But HS is more than a lesion-counting contest. Researchers are also paying closer attention to pain, drainage, odor, fatigue, sleep, sexual health, mobility, depression, anxiety, and work productivity. This is crucial because a patient can have fewer inflammatory nodules and still be struggling if one draining tunnel ruins sleep or makes sitting through a meeting feel like a medieval endurance test.
Good HS research also needs diversity. HS affects people across racial and ethnic backgrounds, and it is often underdiagnosed in people with skin of color. Clinical trials must represent the real-world population living with the disease. If a treatment is tested mostly in narrow populations, doctors may have less confidence applying the data broadly.
Beyond Drugs: Surgery, Lasers, and Combination Care
The future of hidradenitis suppurativa treatment is not only about biologics and pills. Surgery and procedural care remain essential, especially for persistent tunnels and scarred areas. Deroofing can remove the top of a chronic tunnel so the area can heal from the inside out. Wide excision may be considered for severe, localized disease. Carbon dioxide laser treatment and laser hair reduction may help selected patients, particularly when hair follicles and repeated friction contribute to flares.
Research increasingly supports combination care. A patient might use a biologic to reduce inflammation, surgery to address established tunnels, wound care to manage drainage, and lifestyle changes to reduce triggers. This is not “throwing everything at the wall.” It is more like building a team: the biologic handles immune overreaction, the surgeon handles damaged architecture, wound care handles the daily logistics, and the patient gets to stop feeling like their skin is running an unauthorized construction site.
Quality of Life Is Finally Getting the Attention It Deserves
One of the most important developments in HS research is the recognition that quality of life is not a side note. HS can affect clothing choices, intimacy, exercise, sleep, body image, mental health, and social confidence. People may avoid gyms, pools, dating, long car rides, or even white pants. Honestly, white pants are risky for everyone, but HS adds a whole new level of suspense.
Modern clinical trials increasingly include patient-reported outcomes. These may measure pain, itch, drainage, odor, embarrassment, and daily functioning. That matters because doctors can count nodules, but patients live inside the experience. A treatment that reduces inflammation but does not reduce pain or drainage may not feel like enough.
Practical Examples: How New Research Could Change Care
Imagine a patient with stage II HS who has tried oral antibiotics multiple times. The flares improve briefly, then return. In the past, that patient might have cycled through antibiotic courses for years. Today, a dermatologist may consider biologic therapy earlier, especially if the disease is scarring, painful, or interfering with daily life.
Now imagine another patient who tried adalimumab and had only partial improvement. Newer IL-17 options may offer a different pathway. If the patient has persistent tunnels, a dermatologist might combine medical therapy with deroofing or surgical management. If future oral therapies such as JAK inhibitors become approved and appropriate, that could add another option for patients who prefer pills or need an alternative mechanism.
A third patient may have early HS with flares triggered by friction and shaving. Research does not mean that patient must jump straight to advanced therapy. Laser hair reduction, topical therapy, weight-neutral friction strategies, gentle cleansing, and early dermatology follow-up may help prevent progression. The best treatment is not always the newest; it is the one matched to the patient.
What Patients Should Ask About Clinical Trials
Clinical trials can offer access to investigational treatments and expert monitoring, but they are not a shortcut or guaranteed cure. Patients considering a trial should ask what phase the study is in, what the drug targets, whether placebo is involved, how long the study lasts, what visits and lab tests are required, what side effects are known, and what happens after the trial ends.
It is also wise to ask whether current medications must be stopped. Some trials exclude people who recently used biologics, antibiotics, steroids, or certain immune therapies. Others may include patients who previously failed TNF inhibitors. The details matter. Clinical trial paperwork can feel like reading a phone contract written by a committee of caffeinated lawyers, but a good research coordinator can explain it in plain language.
The Future of Hidradenitis Suppurativa Research
The future of HS research is likely to move in several directions at once. First, more targeted immune therapies will continue to emerge. Second, researchers will look for biomarkers that predict which patient is likely to respond to which treatment. Third, combination strategies may become more refined, especially biologic-plus-surgery approaches. Fourth, studies may explore the microbiome, genetics, metabolic health, hormones, and environmental triggers in more detail.
The ultimate goal is personalized HS care. Instead of making every patient climb the same treatment ladder, doctors may eventually use disease patterns, blood markers, lesion type, tunnel burden, family history, and immune signatures to choose therapy more intelligently. That would be a major upgrade from trial-and-error medicine, also known as “let us try this and hope your skin does not send a strongly worded complaint.”
Experience-Based Insights: Living With HS While Research Moves Forward
People living with hidradenitis suppurativa often become experts in a disease they never asked to study. They learn which fabrics reduce friction, which bandages stay put, which soaps do not start a rebellion, and which chairs should be avoided during a flare. This lived experience is not “extra” information. It is data from the front lines.
One common experience is the long delay before diagnosis. Many patients report years of being treated for boils, cysts, acne, or infections before someone finally says the words “hidradenitis suppurativa.” That delay can be emotionally exhausting. By the time a patient reaches a dermatologist, they may already have scarring, tunnels, and a deep suspicion of every new cream offered to them. Research can help here by improving awareness among primary care clinicians, urgent care providers, gynecologists, pediatricians, and emergency departments.
Another experience is the frustration of invisible planning. HS patients often plan around pain and drainage in ways others never see. A simple outing may require gauze, extra underwear, dark clothing, pain medication, and an exit strategy. Travel can become complicated. Exercise may help general health but also cause friction and sweating that trigger symptoms. Dating can bring anxiety. Workdays can become miserable when a lesion is located exactly where sitting, walking, or lifting turns into a negotiation.
This is why newer clinical trials should keep measuring quality-of-life outcomes, not just lesion counts. If a treatment reduces abscesses but the patient still cannot sleep, exercise, work comfortably, or feel safe in their clothes, the job is not finished. HS care should aim for fewer flares, less pain, less drainage, better mobility, better sleep, and more confidence. In other words: not just better skin, but a bigger life.
Patients also learn that communication with clinicians matters. A useful HS appointment often includes photos of flares, a symptom diary, a list of previous medications, menstrual or hormonal patterns if relevant, pain scores, drainage patterns, and honest discussion about mental health. This information helps dermatologists understand the disease between visits. HS loves to behave like a villain who disappears right before the detective arrives, so documentation can be powerful.
For people considering biologics or clinical trials, personal priorities matter. Some patients want the strongest possible reduction in inflammation. Others worry about injections, infection risk, cost, pregnancy planning, lab monitoring, or time off for appointments. Good care should respect these concerns. Shared decision-making is not a decorative phrase; it is how chronic disease treatment becomes realistic.
Support communities can also help, especially when they share practical tips without selling miracle cures. HS has attracted plenty of internet myths, from extreme diets to suspicious “detox” routines. Some lifestyle changes may help individual patients, but no one should be shamed into believing they caused their disease. HS is already rude enough. It does not need a motivational speaker with bad science.
The most hopeful experience-related message is this: HS research is moving. For a long time, patients felt ignored. Now, new treatments and clinical trials are expanding rapidly. Not every drug will work for every person, and no article should pretend that progress erases the daily burden of HS. But the direction is encouraging. More pathways are being studied, more outcomes are being measured, and more clinicians understand that HS deserves serious, long-term care.
Conclusion: A New Era for HS Treatment
Hidradenitis suppurativa research is changing the future of care. Approved biologics such as adalimumab, secukinumab, and bimekizumab have expanded treatment options for moderate-to-severe HS. Investigational therapies such as povorcitinib, sonelokimab, izokibep, lutikizumab, and spesolimab show how researchers are exploring multiple immune pathways rather than relying on one strategy.
The most important takeaway is that HS deserves early diagnosis, individualized care, and long-term management. Patients should not have to spend years being told they simply have boils or bad luck. The science is catching up, and with better clinical trials, more diverse research, smarter endpoints, and stronger patient advocacy, the future of hidradenitis suppurativa treatment looks more hopeful than it has in decades.
